Pharmaceutical

Rovia Clinical Research Launches as Parent Company to East Coast Institute for Research, Universal Axon Clinical Research, and IMIC Inc. Clinical Research Center

JACKSONVILLE, Fla., Sept. 26, 2024 /PRNewswire/ -- Rovia Clinical Research is excited to announce the creation of its clinical research…

4 months ago

LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore,…

4 months ago

PharmaCord Announces Completion of Permira Investment

Investment will enable PharmaCord to accelerate its technology roadmap and expand into additional commercialization service lines for its life sciences…

4 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

4 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring…

4 months ago

Interim results for the six months ended June 30, 2024

September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024…

4 months ago

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and…

4 months ago

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

CUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

4 months ago

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

4 months ago